There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and Alimera (ALIM – Research Report) with bullish sentiments.
BioLife Solutions (BLFS)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on BioLife Solutions, with a price target of $21.00. The company’s shares closed last Thursday at $15.86.
According to TipRanks.com, Hewitt is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $23.17 average price target, which is a 54.2% upside from current levels. In a report issued on April 4, Jefferies also initiated coverage with a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
Alimera (ALIM)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Alimera today and set a price target of $8.00. The company’s shares closed last Thursday at $3.44.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alimera with a $8.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BLFS: